All News

COVID Test Antibody

Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

d MedPage Today

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article
xray%20spine%20films_0.jpg

BE MOBILE 1 Study - Bimekizumab in Non-Radiographic Axial Spondyloarthritis

d Jack Cush, MD

Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
gout target T2T

Does T2T Lead to Fewer Gout Flares?

d Jack Cush, MD

Lancet Rheumatology reports that a treat-to-target (T2T) goal of average serum urate less than 6 mg/dL is associated with an absence of gout flares and a reduction in the number of flares in the next 12 months.

Read Article
hip.fx2_.jpg

Fracture Risk with Osteoporosis Drug Holidays

d Jack Cush, MD

While bisphosphonate drug holidays are recommended, there are few comparative studies.

Read Article
Using SKG mouse model of adjuvant induced SpA and enthesitis, neutrophils, and inducible IL-23, were shown to play an important role in early murine spondyloarthritis-related enthesitis. https://t.co/wlHXkNbvR7

Links:

Dr. John Cush RheumNow ( View Tweet)

192 early arthritis & 693 early arthralgia underwent the MTP-squeeze-test (MTPsqT) & MRI. Synovitis & intermetatarsal bursitis (IMB) were assoc w/ MTPsqT. In EA, MTPsqT +, 79% had synovitis or IMB: 12% synovitis, 15% IMB & 52% had both. https://t.co/Ojwb8KkmLu

Links:

Dr. John Cush RheumNow ( View Tweet)

ASK CUSH ANYTHING! Have a Rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/LAC6XrYEyN https://t.co/POGHk7Ibq2

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved 2 JAK inhibitors for use in severe atopic dermatitis (eczema) - Abbvies upadacitinib (Rinvoq) and Pfizers abrocitinib (Cibinqo). https://t.co/WpCehmB7Vz https://t.co/qKoqV08Z86

Links:

Dr. John Cush RheumNow ( View Tweet)

J Rheum reports rheums may not be adequately screening for HBV, HCV when using tofacitinib & tocilizumab, despite rec's from CDC, AASLD, PI (but not ACR) to do so. TCZ & TOFA had partial screening (45% & 50%) or no screening (26% & 26%) https://t.co/y28kSJ1JgA

Links:

Dr. John Cush RheumNow ( View Tweet)

Lupus metanalysis of 41 studies, 17,270 pts shows that REMISSION was maintaned for 1 year in 42–88% of pts, and 5 yrs in 21–70%. Remission assoc w/ older age @dx, lower Dz activity, NO major organ involve. REM had less damage, better QOL https://t.co/1zPcITcYMo

Links:

Dr. John Cush RheumNow ( View Tweet)

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients  https://t.co/dzDuza09JW https://t.co/HqL7nWdaP0

Links:

Dr. John Cush RheumNow ( View Tweet)
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/c7oLLCllM8 https://t.co/EGCGFilnVv

Links:

Dr. John Cush RheumNow ( View Tweet)
World Health Organization has recommended baricitinib & sotrovimab for COVID-19 (both already given EUA by the FDA). BARI (+/- steroids) given as 4 mg qd to severe hospitalized COVID. Sotrovimab, is for outpt, less severe disease. https://t.co/Hv8YdWUoYk https://t.co/l98zcyfGRk https://t.co/RAHKhqPWjp

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/VIcwcPwbjn

Links:

Dr. John Cush RheumNow ( View Tweet)

Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/Ef4b1fYwkw

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/VMEMLod8EP https://t.co/O6l5eLfFxo

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast! Dr. Cush reviews the news and journal articles from the past week on RheumNow. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogrens. https://t.co/A2Kw7rtei6 https://t.co/U6tdmUkP73 https://t.co/Opo5cYc8UB

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/72P5EHwD8l

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/o2b1kwZ9QG https://t.co/ayaDlpl7DI

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/lY1MVpBoF1

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×